Mastering chemotherapy dose reduction in elderly cancer patients

Published:August 08, 2007DOI:


      Cancer is mainly a disease of the elderly but clinical studies have generally excluded the elderly population for various reasons. Chemotherapy is one of the strongest weapons against (metastatic) cancer, but its use in the elderly has been limited due to fear of inducing toxicity. This review points out 10 recommendations that need to be taken into account when prescribing chemotherapy to elderly patients: aim of chemotherapy, specific pharmacological data for specific chemotherapeutics, treatment individualisation, alternatives to cytotoxic chemotherapy, comprehensive geriatric assessment, supportive therapy, hydration status, drug interactions, and compliance. Each of these topics will be reviewed here trying to give concrete recommendations for clinical practice.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wildiers H.
        • Highley M.S.
        • de Bruijn E.A.
        • van Oosterom A.T.
        Pharmacology of anticancer drugs in the elderly population.
        Clin Pharmacokinet. 2003; 42: 1213-1242
        • Balducci L.
        • Yates J.
        General guidelines for the management of older patients with cancer.
        Oncology (Huntingt). 2000; 14: 221-227
        • De Jr., V.V.
        • Hubbard S.M.
        • Longo D.L.
        The chemotherapy of lymphomas: looking back moving forward – the Richard and Hinda Rosenthal Foundation award lecture.
        Cancer Res. 1987; 47: 5810-5824
        • Bonadonna G.
        • Valagussa P.
        Dose–response effect of adjuvant chemotherapy in breast cancer.
        N Engl J Med. 1981; 304: 10-15
        • Hryniuk W.
        • Bush H.
        The importance of dose intensity in chemotherapy of metastatic breast cancer.
        J Clin Oncol. 1984; 2: 1281-1288
        • Balducci L.
        The geriatric cancer patient: equal benefit from equal treatment.
        Cancer Control. 2001; 8: 1-25
        • Chen H.
        • Cantor A.
        • Meyer J.
        • et al.
        Can older cancer patients tolerate chemotherapy?.
        Cancer. 2003; 97: 1107-1114
        • Extermann M.
        • Aapro M.
        • Bernabei R.B.
        • et al.
        Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
        Crit Rev Oncol Hematol. 2005; 55: 241-252
        • Fletcher A.E.
        • Price G.M.
        • Ng E.S.W.
        • et al.
        Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial.
        Lancet. 2004; 364: 1667-1677
        • Smith T.J.
        • Khatcheressian J.
        • Lyman G.H.
        • et al.
        2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
        J Clin Oncol. 2006; 24: 3187-3205
        • Aapro M.S.
        • Cameron D.A.
        • Pettengell R.
        • et al.
        EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
        Eur J Cancer. 2006; 42: 2433-2453
        • Bokemeyer C.
        • Aapro M.S.
        • Courdi A.
        • et al.
        EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
        Eur J Cancer. 2007; 43: 258-270
        • Lichtman S.M.
        • Wildiers H.
        • Launay-Vacher V.
        • Steer C.
        • Chatelut E.
        • Aapro M.
        International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.
        Eur J Cancer. 2007; 43: 14-34
        • Balis F.M.
        Pharmacokinetic drug interactions of commonly used anticancer drugs.
        Clin Pharmacokinet. 1986; 11: 223-235
        • Loadman P.M.
        • Bibby M.C.
        Pharmacokinetic drug interactions with anticancer drugs.
        Clin Pharmacokinet. 1994; 26: 486-500
        • Slaets J.P.J.
        Vulnerability in the elderly: frailty.
        Med Clin North Am. 2006; 90: 593